The valuation of Cempra $CEMP is based mainly on the potential of Solithromycin. The company’s NDAs for the drug has been accepted by the FDA and the oral and IV formulations could be launched by early 2017. For the DCF valuation, I have focused on the U.S. market alone. The company has already submitted MAAs for the drug in the European Union (EU) as well. See my article on Cempra here.